Accurate, balanced evidence-based information about medicines
Description: Cautious approach to new drugs, given the limitations of evidence, failure of clinical trials to define safety profiles and side effects revealed by postmarketing surveillance.

This document is a PDF file. To view PDF documents you will need to download Adobe Reader from the Adobe website.
Please don't show me this PDF gateway page again for this browser session (this will reset when the browser is closed).